Science Current Events | Science News | Brightsurf.com
 

Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC

April 04, 2012
CHICAGO - Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine. The findings were presented here at the AACR Annual Meeting 2012, held March 31 - April 4.

"This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer Center in La Jolla, Calif.

These findings represent an updated long-term survival analysis on patients treated with belagenpumatucel-L, a cell-based allogeneic vaccine derived from four lung cancer cell lines. The open-label study included 75 patients with non-small cell lung cancer (NSCLC) - two patients with stage 2 disease, 12 with stage 3A, 15 with stage 3B and 46 with stage 4. The researchers randomly assigned patients to three dose cohorts: 1.25, 2.5 or 5 × 107 cells/injection.

For all patients, median survival was 14.5 months, and the five-year survival rate was 20 percent. The 40 patients with stage 3B/4 cancer enrolled in the second and third dose cohorts had a median survival of 15.9 months and a one-year survival rate of 61 percent, a two-year survival rate of 41 percent and a five-year survival rate of 18 percent.

Patients with stage 3B/4 nonprogressive disease after chemotherapy had a median survival of 44.4 months; five-year survival was 50 percent, which is "unheard of for patients with NSCLC," Bazhenova said.

In contrast, patients who progressed after front-line chemotherapy had a median survival rate of 14.1 months and a 9.1 percent five-year survival rate.

Bazhenova said that although these results are intriguing, they must be confirmed in a phase III clinical trial, which is currently under way in eight countries.

American Association for Cancer Research


Related Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles


Early stage NSCLC patients with low tumor metabolic activity have longer survival
Low pre-surgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer (NSCLC) is associated with increased overall survival and a longer time before tumor recurrence.

SDSC/UCSD study uncovers mechanisms of cancer-causing mutations
Researchers at the San Diego Supercomputer Center (SDSC) and the Moores Cancer Center at the University of California, San Diego, have described for the first time the molecular mechanism of cancer development caused by well-known "resistance" mutations in the gene called epidermal growth factor receptor (EGFR).

Concurrent chemoradiation treatment at high-volume facilities improves survival for NSCLC
Patients treated with definitive concurrent chemotherapy and radiation therapy (CCRT) for stage III non-small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers.

In vivo CRISPR-Cas9 screen sheds light on cancer metastasis and tumor evolution
For the first time, CRISPR-Cas9 gene-editing technology has been employed in a whole organism model to systematically target every gene in the genome.

Restoring ability to halt cell division may protect lung cells from cancer
Researchers led by a team at the University of Illinois at Chicago, have identified a novel role for a signaling mechanism in lung cells that permanently places them into a state of suspended animation called senescence.

Blood samples as surrogates for tumor biopsies in patients with lung cancer
A study examined the feasibility of using circulating free DNA (cfDNA) from blood samples of patients with advanced non-small-cell lung cancer as a surrogate for tumor biopsies to determine tumor-causing epidermal growth factor receptor (EGFR) mutations and then correlate that with expected patient outcomes, according to a study published online by JAMA Oncology.

Online education tool helps bridge gaps in therapeutic decision-making for advanced NSCLC
A new interactive online tool helps educate practicing oncologists worldwide with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) based on a patient's molecular and clinical characteristics by providing feedback from an expert panel.

Whose numbers determine cost-effectiveness of targeted anti-cancer therapies?
Health economics helps insurers, health care systems and providers make treatment decisions based on the cost of extra "units" of health arising from a specific treatment.

Testing for EGFR mutations and ALK rearrangements is cost-effective in NSCLC
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.

Moffitt researchers develop novel approach to visualize, measure protein complexes in tumors
Cancer diagnosis and treatment decisions are often hampered by a lack of knowledge of the biological processes occurring within the tumor.
More Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC


This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

OPDIVO (Nivolumab): Treats unresectable or Metastatic Melanoma (skin cancer) and Metastatic Squamous Non-Small Cell Lung Cancer

OPDIVO (Nivolumab): Treats unresectable or Metastatic Melanoma (skin cancer) and Metastatic Squamous Non-Small Cell Lung Cancer
by James Lee Anderson (Author)


“Although, your health condition may impact your everyday life, do not let it define who you are.” OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. OPDIVO (nivolumab) is also indicated for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. OPDIVO (nivolumab) treat your melanoma or lung cancer by working with your immune system. OPDIVO can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to...

Lung Cancer

Lung Cancer
by Jack A. Roth (Editor), Waun Ki Hong (Editor), Ritsuko U. Komaki (Editor)


The best and most concise single source for state-of-the-art diagnosis and treatment of lung cancer –newly revised, updated, and expanded.

Lung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. In 2010, about 15% of all cancer diagnoses and 30% of all cancer deaths were due to lung cancer. Needless to say, there is a great need for more rapid advancements in diagnosis and treatment of this devastating disease. Here is the comprehensively revised, updated, and expanded edition of the well-established, evidence-based reference book that deals with the most recent advances in lung cancer prevention, screening, diagnosis, research, and treatment for the clinician. Edited and...

Medifocus Guidebook on: Non-Small Cell Lung Cancer

Medifocus Guidebook on: Non-Small Cell Lung Cancer
by Medifocus.com (Author), Elliot Jacob PhD. (Editor)


The MediFocus Guidebook on Non-Small Cell Lung Cancer is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Non-Small Cell Lung Cancer, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Non-Small Cell Lung Cancer, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,...

What You Need to Know About Small Cell Lung Cancer - It's Your Life, Live It! (Volume 1)

What You Need to Know About Small Cell Lung Cancer - It's Your Life, Live It! (Volume 1)
by Michael Braham (Author)


Selecting the right treatment can literally make the difference between life and death. It is important to have the peace-of-mind knowing that you have done everything possible to help fight Small Cell Lung cancer successfully. The Cancer Group Institute's book explains, in plain English, the definition, types, frequency, risk factors, symptoms, historic and latest effective treatment for Small Cell Lung cancer. We describe surgery, radiation, chemotherapy and immune therapies. We tell you everything you must know to help make the right choices today for a Small Cell Lung cancer problem. Some of the Department Heads, Hospitals and Residents using our materials are Mayo Clinic, Harvard University, Columbia, NYU, UCLA, Johns Hopkins, MD Anderson Cancer Center Orlando, Tift Regional...

Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine (Pocket Notebook)

Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine (Pocket Notebook)
by Marc S. Sabatine MD (Author)


Prepared by residents and attending physicians at Massachusetts General Hospital, the 5th edition of Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine provides key clinical information and solutions to common problems faced in the practice of internal medicine.Designed to fit in a pocket, this 6-ring looseleaf binder tackles the diagnosis and treatment of the most common disorders in cardiology, pulmonary medicine, gastroenterology, nephrology, hematology-oncology, infectious diseases, endocrinology, rheumatology, and neurology.Bulleted lists combined with tables and algorithms allow busy clinicians to find the information they need rapidly. A 16-page color insert displays classic normal and abnormal radiographs, CT scans, echocardiograms, peripheral blood...

Prioritization, Delegation, and Assignment: Practice Exercises for the NCLEX Examination, 3e

Prioritization, Delegation, and Assignment: Practice Exercises for the NCLEX Examination, 3e
by Linda A. LaCharity PhD RN (Author), Candice K. Kumagai RN MSN (Author), Barbara Bartz RN MN CCRN (Author)


The only NCLEX review book on the market with a focus on prioritization, delegation, and patient assignment - just like the current NCLEX Examination itself! Using a unique simple-to-complex approach, Prioritization, Delegation, and Assignment: Practice Exercises for the NCLEX® Examination, 3rd Edition establishes your foundational knowledge in management of care, then provides exercises of increasing difficulty to help you build confidence in your prioritization, delegation, and patient assignment skills.UNIQUE! Emphasis on the NCLEX Examination's management-of-care focus addresses the heavy emphasis on prioritization, delegation, and patient assignment in the current NCLEX Examination (17-23% of the 2013 NCLEX-RN Exam).UNIQUE! Three-part organization establishes foundational knowledge...

21st Century Adult Cancer Sourcebook: Non-Small Cell Lung Cancer (NSCLC) - Clinical Data for Patients, Families, and Physicians

21st Century Adult Cancer Sourcebook: Non-Small Cell Lung Cancer (NSCLC) - Clinical Data for Patients, Families, and Physicians
by Progressive Management


Authoritative information and practical advice from the nation's cancer experts about non-small cell lung cancer (NSCLC) includes official medical data on signs, symptoms, early detection, diagnostic testing, risk factors and prevention, treatment options, surgery, radiation, drugs, chemotherapy, staging, biology, prognosis, and survival, with a complete glossary of technical medical terms and current references.

Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive in-depth compilation gives empowered patients, families, caregivers, nurses, and physicians the knowledge they need to understand the diagnosis and treatment of non-small cell lung cancer (NSCLC).

Non-small cell lung cancer is a disease...

  QuickFACTS™ Non-Small Cell Lung Cancer, Third Edition - 2015: What You Need to Know - Now
by American Cancer Society


According to estimates, more than 244,000 new cases of lung cancer will be diagnosed in the United States this year; of those 85 to 90 percent will be non-small cell lung cancer. There are three main subtypes of this lung cancer, including squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. The cells in these subtypes look very different under a microscope, but the approach to treating them is often very similar. This QuickFACTS reference book on non-small cell lung cancer covers everything from risk factors for the disease to living well after treatment, with sections on the causes of non-small cell lung cancer, early detection, diagnosis and staging, and treatment. An essential guide for a newly diagnosed patient, this book covers the...

What You Need to Know About Non-Small Cell Lung Cancer - It's Your Life, Live It!

What You Need to Know About Non-Small Cell Lung Cancer - It's Your Life, Live It!
by Cancer Group Institute


Selecting the right treatment can literally make the difference between life and death. It is important to have the peace-of-mind knowing that you have done everything possible to help fight Non-Small Cell Lung cancer successfully.

The Cancer Group Institute's book explains, in plain English, the definition, types, frequency, risk factors, symptoms, historic and latest effective treatment for Non-Small Cell Lung cancer. We describe surgery, radiation, chemotherapy and immune therapies. We tell you everything you must know to help make the right choices today for a Non-Small Cell Lung cancer problem.

We are honored to inform you that many leading hospitals use our books in their medical library to be used by physicians. They are Harvard University, Columbia, NYU, ...

© 2015 BrightSurf.com